Elite Journal of Health Sciences. Volume 2 Issue 7(2024), Pp. 36-43
https://epjournals.com/journals/EJHS

Complement System Activation in Vaso-Occlusive Crisis of Sickle Cell Anemia

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle cell anemia (SCA) is a hereditary blood disorder characterized by the production of abnormal hemoglobin S (HbS), leading to the sickling of red blood cells (RBCs) under hypoxic conditions. This sickling phenomenon results in various complications, including vaso-occlusive crises (VOCs), which are acute episodes of pain and ischemia caused by the obstruction of small blood vessels. Recent studies have highlighted the critical role of the complement system in the pathophysiology of SCA, particularly in relation to the activation of inflammatory pathways that contribute to VOCs. The complement system, a crucial component of the innate immune response, can be activated through classical, alternative, and lectin pathways, each leading to the generation of pro-inflammatory mediators. In the context of SCA, complement activation enhances inflammation, promotes endothelial dysfunction, and facilitates the adhesion of sickled RBCs to the vascular endothelium, thereby exacerbating the risk of microvascular occlusion. Additionally, the interaction between activated complement components and immune cells contributes to the amplification of the inflammatory response, creating a vicious cycle that perpetuates the occurrence of VOCs.

Keywords*: sickle cell anemia, vaso-occlusive crisis, complement system, inflammation, immune response, therapeutic targets.*

Introduction

Sickle cell anemia (SCA) is a hereditary blood disorder caused by a mutation in the β-globin gene, resulting in the production of abnormal hemoglobin S (HbS). Under low oxygen conditions, HbS polymerizes, leading to the deformation of red blood cells (RBCs) into a characteristic sickle shape. This sickling process significantly impairs the deformability of RBCs, increasing their propensity to obstruct blood vessels, which can trigger a cascade of events leading to vaso-occlusive crises (VOCs). These episodes are characterized by acute pain, ischemia, and organ dysfunction, representing a major source of morbidity and mortality in affected individuals.[1-5] The pathophysiology of VOCs is multifactorial and involves a complex interplay between various cellular and molecular mechanisms. Inflammation, oxidative stress, endothelial dysfunction, and alterations in blood rheology all contribute to the development of VOCs. In particular, the role of the innate immune system in mediating the inflammatory response during VOCs has garnered increasing attention. A key player in this response is the complement system, a critical component of innate immunity that can enhance inflammation and modulate vascular function.[6-10] The complement system comprises a series of proteins that circulate in an inactive form in the blood. Activation of the complement system can occur through three primary pathways: the classical pathway, initiated by antibody-antigen complexes; the alternative pathway, which is activated spontaneously; and the lectin pathway, triggered by the binding of lectins to carbohydrate

structures on pathogens or damaged cells. Once activated, complement components can lead to the generation of pro-inflammatory mediators, opsonization of pathogens, and the formation of the membrane attack complex (MAC), which can lyse target cells.[11-15]

In the context of sickle cell anemia, recent studies have demonstrated that complement activation is closely linked to the pathogenesis of vaso-occlusive crises. Elevated levels of complement activation products, such as C3a and C5a, have been observed in individuals with SCA, correlating with disease severity and the frequency of VOCs. These complement activation products act as potent inflammatory mediators, promoting vasodilation, increasing vascular permeability, and facilitating the recruitment of leukocytes to sites of inflammation, all of which exacerbate the likelihood of vaso-occlusion.[16-18] The interaction between activated complement components and sickled RBCs is critical in the context of VOCs. Sickled RBCs can expose surface molecules that promote complement deposition, leading to enhanced inflammation and impaired endothelial function. Additionally, the accumulation of activated complement components can contribute to the formation of a pro-inflammatory microenvironment, further exacerbating the inflammatory response and increasing the risk of microvascular obstruction.[19-23] Endothelial dysfunction is another crucial aspect of the pathophysiology of VOCs in sickle cell anemia. The complement system plays a significant role in modulating endothelial function, with activated complement components promoting the expression of adhesion molecules on endothelial cells. This increase in adhesion molecules facilitates the interaction between sickled RBCs and the endothelium, contributing to the obstruction of blood flow and the development of VOCs. Furthermore, complement activation can influence the behavior of leukocytes during vaso-occlusive crises. Activated complement components serve as chemoattractants for neutrophils and monocytes, enhancing their recruitment to inflamed tissues. Once at the site of inflammation, these leukocytes can release additional pro-inflammatory mediators, creating a positive feedback loop that perpetuates the inflammatory response and contributes to the severity of VOCs.[24-28]

Recent studies have also highlighted the correlation between complement activation levels and disease severity in sickle cell anemia. Higher levels of complement components, such as C5a, have been associated with increased pain severity and a greater frequency of vaso-occlusive crises. This relationship suggests that complement activation may serve as a potential biomarker for predicting disease progression and assessing the risk of VOCs in affected individuals. Given the significant role of the complement system in the pathogenesis of vaso-occlusive crises, targeting complement activation presents a promising therapeutic strategy for managing sickle cell anemia. Inhibiting specific complement components or blocking complement activation pathways may help to reduce inflammation, mitigate endothelial dysfunction, and ultimately decrease the incidence of VOCs. Several complement inhibitors are currently under investigation, and their potential application in SCA offers hope for improving patient outcomes and quality of life.[29-33]

Mechanisms of Complement System Activation in Vaso-Occlusive Crisis

The classical pathway of complement activation is initiated when antibodies bind to antigens, forming immune complexes. In sickle cell anemia (SCA), the abnormal shape and properties of sickled red blood cells (RBCs) can lead to the formation of immune complexes. These complexes can activate the classical pathway, leading to the cleavage of complement component C4 and the subsequent generation of C3 convertase. This activation results in the generation of complement activation products such as C3a and C5a, which are potent anaphylatoxins that promote inflammation, increase vascular permeability, and recruit immune cells to sites of tissue damage,

thus contributing to the inflammatory response during vaso-occlusive crises (VOCs).[34-38] The alternative pathway of complement activation can be initiated spontaneously, independent of antibodies. In the context of SCA, sickled RBCs can trigger this pathway through the spontaneous hydrolysis of C3, leading to the formation of C3b. This C3b can bind to various surfaces, including sickled RBCs, promoting the formation of the C3 convertase and further amplifying complement activation. The alternative pathway's activation contributes to the accumulation of pro-inflammatory complement components, which enhances the inflammatory milieu and promotes leukocyte adhesion to the endothelium, exacerbating the risk of microvascular occlusion during VOCs.[39-43]

The lectin pathway of complement activation is initiated by the binding of lectins, such as mannose-binding lectin (MBL), to carbohydrate structures on the surface of pathogens or damaged cells. In sickle cell anemia, altered surface properties of sickled RBCs may expose specific carbohydrate structures that can activate the lectin pathway. Upon binding, MBL activates serine proteases that cleave C4 and C2, leading to the formation of the C3 convertase and subsequent generation of complement activation products. This pathway further contributes to the amplification of the complement cascade, enhancing the inflammatory response and promoting vascular dysfunction during VOCs.[44-48] Activated complement components, particularly C3a and C5a, serve as potent pro-inflammatory mediators that contribute to the pathophysiology of VOCs in SCA. C3a and C5a can induce the release of histamine from mast cells, leading to vasodilation and increased vascular permeability. Additionally, these anaphylatoxins can enhance the expression of adhesion molecules on endothelial cells, facilitating the adhesion of leukocytes and sickled RBCs to the vessel wall. This increased adhesion can lead to further obstruction of blood flow and exacerbation of ischemia, promoting the occurrence of vaso-occlusive crises.[49-53]

Complement activation has significant effects on endothelial cells, which play a crucial role in maintaining vascular integrity and homeostasis. Activated complement components can induce endothelial dysfunction by promoting the expression of adhesion molecules such as E-selectin, P-selectin, and intercellular adhesion molecule-1 (ICAM-1). This enhanced expression increases the adhesion of sickled RBCs and leukocytes to the endothelium, contributing to the development of microvascular occlusion during VOCs. Additionally, complement activation can lead to the release of pro-inflammatory cytokines from endothelial cells, further amplifying the inflammatory response.[54-58]

Complement activation can also contribute to the generation of oxidative stress, which is a significant factor in the pathophysiology of SCA. Activated complement components can recruit inflammatory cells, such as neutrophils, to sites of complement activation. These neutrophils produce reactive oxygen species (ROS) that can damage endothelial cells, exacerbate inflammation, and promote the sickling of RBCs. The resulting oxidative stress can further impair vascular function and contribute to the development of vaso-occlusive crises.[59-63] The complement system interacts closely with leukocytes, influencing their activation and migration during vaso-occlusive crises. Complement activation products, particularly C5a, act as potent chemoattractants for neutrophils and monocytes. This recruitment of leukocytes to inflamed tissues enhances their activation and promotes the release of additional pro-inflammatory mediators, creating a positive feedback loop that perpetuates the inflammatory response. The increased presence of leukocytes can lead to further obstruction of blood flow, contributing to the severity of VOCs.[64-66] Research has shown a correlation between complement activation and disease severity in sickle cell anemia.

Elevated levels of complement activation products, such as C3a and C5a, have been associated with an increased frequency of vaso-occlusive crises and greater pain severity. This relationship suggests that complement activation may serve as a biomarker for disease progression and highlights the potential for targeting the complement system as a therapeutic strategy in SCA.[67] The membrane attack complex (MAC), formed by the terminal components of the complement cascade (C5b, C6, C7, C8, and C9), can also play a role in the pathogenesis of vaso-occlusive crises. The formation of the MAC on sickled RBCs and endothelial cells can lead to cell lysis and further release of inflammatory mediators, exacerbating the inflammatory response. Additionally, the deposition of MAC on the endothelium can disrupt vascular integrity, increasing permeability and promoting the adhesion of sickled RBCs and leukocytes, ultimately contributing to the development of microvascular occlusion.[68]

Conclusion

In conclusion, the complement system plays a critical role in the pathogenesis of vaso-occlusive crises (VOCs) in sickle cell anemia (SCA). Through the activation of classical, alternative, and lectin pathways, complement activation leads to the generation of pro-inflammatory mediators that amplify the inflammatory response, promote endothelial dysfunction, and facilitate the adhesion of sickled red blood cells (RBCs) to the vascular endothelium. This complex interplay of mechanisms contributes to the obstruction of microvasculature, resulting in the acute pain and ischemia characteristic of VOCs. The role of the complement system in promoting oxidative stress and leukocyte recruitment further underscores its significance in the inflammatory landscape of SCA. Additionally, the formation of the membrane attack complex can exacerbate endothelial injury, perpetuating a cycle of inflammation and vaso-occlusion. Targeting the complement system presents a promising therapeutic avenue for managing VOCs in sickle cell anemia. Inhibiting specific complement components or pathways may help reduce inflammation, improve endothelial function, and ultimately decrease the incidence of vaso-occlusive crises.

References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018;19(1):113-147.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.

9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
10. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
11. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circulation research. 2007 Sep 28;101(7):654-662.
12. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. American journal of biomedical science & research. 2022;15(2):153.
13. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
14. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):67-80.
26. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).

27. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Annals of hematology. 2010; 89:877-882.
28. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.
29. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
30. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
36. Tsikas D. Does the inhibitory action of asymmetric dimethylarginine (ADMA) on the endothelial nitric oxide synthase activity explain its importance in the cardiovascular system? The ADMA paradox. Journal of Controversies in Biomedical Research. 2017;3(1):16-22.
37. Martins R, Knapp S. Heme and hemolysis in innate immunity: adding insult to injury. Current opinion in immunology. 2018; 50:14-20.
38. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-arginine in nitric oxide synthesis and health in humans. Amino acids in nutrition and health: Amino acids in gene expression, metabolic regulation, and exercising performance. 2021:167-87.
39. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
40. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of

agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
41. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
42. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
43. Roberts BW, Mitchell J, Kilgannon JH, Chansky ME, Trzeciak S. Nitric oxide donor agents for the treatment of ischemia/reperfusion injury in human subjects: a systematic review. Shock. 2013;39(3):229-339.
44. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
45. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
46. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
47. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
48. Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annual review of pharmacology and toxicology. 2023;63(1):585-615.
49. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
50. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
51. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
52. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
53. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
54. Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Frontiers in immunology. 2020; 11:938.
55. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
56. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
57. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
58. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.

59. Bontempo P, Capasso L, De Masi L, Nebbioso A, Rigano D. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions. Nutrients. 2024;16(15):2399.
60. Cao M, Zhao Y, He H, Yue R, Pan L, Hu H, Ren Y, Qin Q, Yi X, Yin T, Ma L. New applications of HBOC-201: a 25-year review of the literature. Frontiers in Medicine. 2021; 8:794561.
61. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal. 2003;3(4):215-226.
62. Obeagu EI. Redox Signaling and Vaso-Occlusive Crisis in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 26-35
63. Obeagu EI. Hypoxia-Induced Signaling in the Pathogenesis of Vaso-Occlusive Crisis. *Elite Journal of Haematology, 2024; 2(7):* 36-43
64. Obeagu EI. Neurovascular Regulation and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 41-48
65. Obeagu EI. Bone Marrow Microenvironment and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 49-56
66. Obeagu EI. Role of G6PD Deficiency in Vaso-Occlusive Phenomena in Sickle Cell Disease. Elite Journal of Medical Sciences, 2024; 2(7):49-57
67. Obeagu EI. Role of the Reticuloendothelial System in Sickle Cell Vaso-Occlusion. Elite Journal of Medical Sciences, 2024; 2(7):58-65
68. Obeagu EI. Role of Myeloid-Derived Suppressor Cells in Vaso-Occlusive Crisis. Elite Journal of Health Science, 2024; 2(7): 28-35